Pathogen inactivation trial suspended
This article was originally published in The Gray Sheet
Executive Summary
Vitex "temporarily" halts patient enrollment in a Phase III study exploring use of its Inactine pathogen inactivation system with red blood cells for an acute-only indication. The decision to suspend enrollment comes a little over a month after a data safety monitoring board cleared the trial despite antibody problems found in Vitex' earlier Phase III trial, which supported a chronic infusion claim (1"The Gray Sheet" Oct. 18, 2004, In Brief). The latter trial was halted a year ago. The acute-only study was suspended because of one patient's immune response to Inactine-treated red cells, Vitex says. Antibody issues also have posed hurdles to clinical development of Baxter/Cerus' Intercept...
You may also be interested in...
Biotechnology News In Brief
Ovarian cancer test study: Four-analyte blood test developed by researchers at the Nevada Cancer Institute and Yale University School of Medicine requires "further improvement" before it is to be recommended for population screening of ovarian cancer, they note in the May 10 Proceedings of the National Academy of Sciences. The assay demonstrated 95% sensitivity and 95% specificity in a blinded cross-validation study involving 106 healthy females and 100 patients with epithelial ovarian cancer (EOC). Nevertheless, the study authors cite 99.6% as a desirable threshold for specificity. They advise that "other proteins previously implicated in EOC discrimination" might enhance the assay, which could be offered to high-risk patients. Follow-up evaluations such as transvaginal ultrasound then could be conducted in patients who test positive twice, the researchers note. The test used ELISA and microarray screening analysis, performed by Qiagen...
Vitex R&D, business developments
Data safety monitoring board clears manufacturer to continue Phase III trial of Inactine pathogen inactivation system to treat red blood cells under an acute-only indication. In 2003, the firm stopped a Phase III trial in red blood cells that supported a chronic transfusion claim, citing problems with antibody formation in sickle cell anemia patients. The firm is seeking shareholder approval for a merger agreement with Panacos Pharmaceuticals...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.